{
    "name": "hydroxyurea",
    "comment": "Rx",
    "other_names": [
        "Droxia",
        "Siklos",
        "hydroxycarbamide",
        "Hydrea"
    ],
    "classes": [
        "Antineoplastics",
        "Antimetabolites"
    ],
    "source": "https://reference.medscape.com/drug/droxia-siklos-hydroxyurea-342100",
    "pregnancy": {
        "common": [
            "There are no studies with the use in pregnant females",
            "Limited data are available on use during pregnancy is insufficient to inform drug-associated risks",
            "In case of an exposure to hydroxyurea of pregnant female patients or pregnant partners of male patients, a careful follow-up with adequate clinical, biological and ultrasonographic examinations should be considered ",
            "Advise pregnant women of the potential risk to a fetus; verify the pregnancy status of females of reproductive potential prior to initiating therapy"
        ],
        "specific": [
            {
                "type": "Fertility",
                "description": [
                    "Based on findings in animals and humans, male fertility may be compromised by treatment; azoospermia or oligospermia has been observed in men; before initiating therapy, inform male patients about the possibility of sperm conservation"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during and for at least 6 months after therapy",
                    "Males of reproductive potential: Use effective contraception during and after treatment for at least 1 year "
                ]
            },
            {
                "type": "Animal data ",
                "description": [
                    "Drugs that affect DNA synthesis, such as hydroxyurea, may be potential mutagenic agents ",
                    "Hydroxyurea administration to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose ",
                    "In rats and rabbits, fetal malformations were observed with partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, and missing lumbar vertebrae",
                    "Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Not recommended during treatment",
            "Unknown whether hydroxyurea is excreted in human milk, the effects of hydroxyurea on the breastfed child, or the effects of hydroxyurea on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "  Myelosuppression",
                    "description": [
                        "Severe myelosuppression may occur",
                        "Do not give if bone marrow function is markedly depressed",
                        "Monitor blood counts at baseline and throughout treatment",
                        "Interrupt treatment and reduce dose as necessary"
                    ]
                },
                {
                    "type": "Malignancies",
                    "description": [
                        "Hydroxyurea is mutagenic and clastogenic, and causes cellular transformation to a tumorigenic phenotype, and is thus unequivocally genotoxic and a presumed transspecies carcinogen that implies a carcinogenic risk to humans; advise sun protection and monitor patients for malignancies",
                        "In patients receiving long-term hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukemias have been reported",
                        "It is unknown whether this leukemogenic effect is secondary to hydroxyurea or is associated with the patients' underlying disease",
                        "The physician and patient must very carefully consider the potential benefits relative to the undefined risk of developing secondary malignancies",
                        "Advise sun protection and monitor patients for malignancies"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Severe anemia, bone marrow depression",
                "WBC <2500/mm³, platelets <100,000/mm³",
                "Pregnancy, lactation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of cutaneous vasculitic toxicities in patients with myeloproliferative disorders, especially with history of or concurrent interferon therapy; avoid use in patients with wounds on the legs (leg ulcers)",
                "Erythrocyte abnormalities reported; self-limiting megaloblastic erythropoiesis reported early in treatment, unrelated to vitamin B12 or folic acid deficiency",
                "Hyperuricemia may occur; adequate hydration, dosage adjustment, or initiation of uricosuric agents may be necessary",
                "Interferes with analytical analyses of the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid and lactic acid, rendering falsely elevated results",
                "Macrocytosis is often seen early in the course of treatment; morphologic change resembles pernicious anemia, but is not related to vitamin B12 or folic acid deficiency; prophylactic folic acid is recommended",
                "Skin cancer reported in patients receiving long-term therapy; advise protection from sun exposure and monitor for development of secondary malignancies",
                "Fetal harm may occur when hydroxyurea is administered to a pregnant woman (see Pregnancy)"
            ],
            "specific": [
                {
                    "type": "Hemolytic anemia",
                    "description": [
                        "Cases of hemolytic anemia in patients treated for myeloproliferative diseases reported",
                        "Patients who develop acute jaundice or hematuria in presence of persistent or worsening of anemia should have laboratory tests evaluated for hemolysis (eg, measurement of serum lactate dehydrogenase, haptoglobin, reticulocyte, unconjugated bilirubin levels, urinalysis, and direct and indirect antiglobulin [Coombs] tests)",
                        "In the setting of confirmed diagnosis of hemolytic anemia and in absence of other causes, discontinue therapy"
                    ]
                },
                {
                    "type": "Pulmonary toxicity",
                    "description": [
                        "Interstitial lung disease including pulmonary fibrosis, lung infiltration, pneumonitis, and alveolitis/allergic alveolitis (including fatal cases) reported in patients treated for myeloproliferative neoplasm",
                        "Safety and effectiveness not established for use in treatment of myeloproliferative neoplasms and use not approved by the FDA",
                        "Monitor patients developing pyrexia, cough, dyspnea, or other respiratory symptoms frequently, investigate and treat promptly; discontinue therapy and manage with corticosteroids"
                    ]
                },
                {
                    "type": "Myelosuppression",
                    "description": [
                        "Evaluate hematologic status prior to and every two weeks during treatment",
                        "Provide supportive care and modify dose or discontinue therapy as needed",
                        "Recovery from myelosuppression is usually observed within 15 days when therapy is interrupted; resume therapy after interruption at a lower dose",
                        "Monitor hematologic parameters more frequently in patients with hepatic impairment receiving therapy",
                        "In patients receiving long-term hydroxyurea for myeloproliferative disorders (a condition for which this drug is not approved), secondary leukemia has been reported",
                        "Some patients, treated at recommended initial dose of 15 mg/kg/day in adults or 20 mg/kg/day in children, have experienced severe or life-threatening myelosuppression"
                    ]
                },
                {
                    "type": "Leukemia",
                    "description": [
                        "Secondary leukemia reported in patients treated long-term for sickle cell disease; leukemia also reported in patients with sickle cell disease and no prior history of treatment with drug",
                        "All patients should be followed up on long-term basis with regular blood counts to detect development of leukemia"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred when hydroxyurea was administered concomitantly with antiretroviral drugs, including didanosine and stavudine",
                        "Concomitant use with a live virus vaccine may potentiate the replication of the vaccine virus and/or may increase the adverse reactions of the vaccine virus and result in severe infections",
                        "Interference with uric acid, urea, or lactic acid assays may falsely elevate results in patients treated with hydroxyurea"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "hydroxyurea decreases effects of adenovirus types 4 and 7 live, oral by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "hydroxyurea, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "BCG intravesical live",
            "description": {
                "common": "hydroxyurea decreases effects of BCG intravesical live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "hydroxyurea decreases effects of BCG vaccine live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "hydroxyurea, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take hydroxyurea for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "hydroxyurea, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "hydroxyurea decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "hydroxyurea, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, hydroxyurea.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "didanosine",
            "description": {
                "common": "hydroxyurea, didanosine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred in HIV patients treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine,  avoid this combination. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "hydroxyurea, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "hydroxyurea decreases effects of influenza virus vaccine quadrivalent, intranasal by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "hydroxyurea, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "hydroxyurea decreases effects of measles mumps and rubella vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "hydroxyurea decreases effects of measles, mumps, rubella and varicella vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of hydroxyurea by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, hydroxyurea.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "hydroxyurea decreases effects of rotavirus oral vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "hydroxyurea decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "stavudine",
            "description": {
                "common": "hydroxyurea, stavudine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred in HIV patients treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine,  avoid this combination. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "hydroxyurea, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "hydroxyurea, tofacitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "hydroxyurea decreases effects of typhoid vaccine live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "hydroxyurea decreases effects of varicella virus vaccine live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "hydroxyurea decreases effects of zoster vaccine live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abatacept",
            "description": {
                "common": "hydroxyurea, abatacept. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, hydroxyurea.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adalimumab",
            "description": {
                "common": "hydroxyurea, adalimumab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alefacept",
            "description": {
                "common": "hydroxyurea, alefacept. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alemtuzumab",
            "description": {
                "common": "alemtuzumab, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "allopurinol",
            "description": {
                "common": "allopurinol, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azacitidine",
            "description": {
                "common": "azacitidine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and hydroxyurea both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belimumab",
            "description": {
                "common": "hydroxyurea, belimumab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendamustine",
            "description": {
                "common": "bendamustine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "hydroxyurea, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "busulfan",
            "description": {
                "common": "busulfan, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "carboplatin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carmustine",
            "description": {
                "common": "carmustine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "hydroxyurea, certolizumab pegol. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "chlorambucil, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cidofovir",
            "description": {
                "common": "cidofovir, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cladribine",
            "description": {
                "common": "cladribine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clofarabine",
            "description": {
                "common": "clofarabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Avoid combination. Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cytarabine",
            "description": {
                "common": "cytarabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "dacarbazine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dactinomycin",
            "description": {
                "common": "dactinomycin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "dasatinib, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daunorubicin",
            "description": {
                "common": "daunorubicin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "decitabine",
            "description": {
                "common": "decitabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "hydroxyurea decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "hydroxyurea, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Combination therapy may lead to increased risk of infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexrazoxane",
            "description": {
                "common": "dexrazoxane, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide, hydroxyurea.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "docetaxel",
            "description": {
                "common": "docetaxel, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin",
            "description": {
                "common": "doxorubicin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin liposomal",
            "description": {
                "common": "doxorubicin liposomal, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "echinacea",
            "description": {
                "common": "echinacea decreases effects of hydroxyurea by Other (see comment). Use Caution/Monitor. \nComment: Echinacea may decrease therapeutic effects of immunosuppressants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epirubicin",
            "description": {
                "common": "epirubicin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estramustine",
            "description": {
                "common": "estramustine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etanercept",
            "description": {
                "common": "hydroxyurea, etanercept. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etoposide",
            "description": {
                "common": "etoposide, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "hydroxyurea increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flucytosine",
            "description": {
                "common": "flucytosine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludarabine",
            "description": {
                "common": "fludarabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "fluorouracil, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "ganciclovir, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "gemcitabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "golimumab",
            "description": {
                "common": "hydroxyurea, golimumab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idarubicin",
            "description": {
                "common": "idarubicin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "infliximab",
            "description": {
                "common": "hydroxyurea, infliximab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "hydroxyurea decreases effects of influenza virus vaccine quadrivalent, cell-cultured by Other (see comment). Use Caution/Monitor. \nComment: Immunosuppressants may decrease the therapeutic effects of vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "interferon alfa 2b",
            "description": {
                "common": "interferon alfa 2b, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "interferon beta 1a",
            "description": {
                "common": "interferon beta 1a, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "interferon gamma 1b",
            "description": {
                "common": "interferon gamma 1b, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan",
            "description": {
                "common": "irinotecan, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "irinotecan liposomal, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ixabepilone",
            "description": {
                "common": "ixabepilone, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leflunomide",
            "description": {
                "common": "hydroxyurea, leflunomide. Other (see comment). Use Caution/Monitor. \nComment: Combination therapy may lead to increased risk of infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenalidomide",
            "description": {
                "common": "lenalidomide, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitomycin",
            "description": {
                "common": "mitomycin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitoxantrone",
            "description": {
                "common": "mitoxantrone, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "hydroxyurea, mycophenolate. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "natalizumab",
            "description": {
                "common": "natalizumab, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Avoid combination. Potential for increased risk of concurrent infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelarabine",
            "description": {
                "common": "nelarabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, hydroxyurea.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "paclitaxel, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "paclitaxel protein bound, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "peginterferon alfa 2a, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentostatin",
            "description": {
                "common": "pentostatin, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "pralatrexate, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "hydroxyurea increases levels of probenecid by Other (see comment). Use Caution/Monitor. \nComment: Dosage adjustment of probenecid may be needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pyrimethamine",
            "description": {
                "common": "pyrimethamine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and hydroxyurea both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "hydroxyurea decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temozolomide",
            "description": {
                "common": "temozolomide, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teniposide",
            "description": {
                "common": "teniposide, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioguanine",
            "description": {
                "common": "thioguanine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiotepa",
            "description": {
                "common": "thiotepa, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Avoid combination. Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "hydroxyurea, tocilizumab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topotecan",
            "description": {
                "common": "topotecan, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, hydroxyurea.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, hydroxyurea.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and hydroxyurea both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "hydroxyurea, ustekinumab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vinblastine",
            "description": {
                "common": "vinblastine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vinorelbine",
            "description": {
                "common": "vinorelbine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "hydroxyurea, zidovudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of myelosuppression."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infections",
            "percent": "39.8"
        },
        {
            "name": "Other infections",
            "percent": "22.7"
        },
        {
            "name": "Bacterial infections",
            "percent": "16"
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": "13.1"
        },
        {
            "name": "Neutropenia",
            "percent": "12.6"
        },
        {
            "name": "Viral infections",
            "percent": "9.9"
        },
        {
            "name": "Fever",
            "percent": "7.7"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "7.4"
        },
        {
            "name": "Other gastrointestinal disorders",
            "percent": "7.4"
        },
        {
            "name": "Headache",
            "percent": "7.4"
        },
        {
            "name": "Vitamin D deficiency",
            "percent": "6.2"
        },
        {
            "name": "Other not SCD",
            "percent": "5.7"
        },
        {
            "name": "related reactions",
            "percent": "4.2"
        },
        {
            "name": "Anemia",
            "percent": "3.7"
        },
        {
            "name": "Skin reactions",
            "percent": "19"
        },
        {
            "name": "Parvovirus B",
            "percent": "3.7"
        },
        {
            "name": "infections",
            "percent": "3.2"
        },
        {
            "name": "Other skin and subcutaneous tissue disorders",
            "percent": "2.7"
        },
        {
            "name": "Other nervous system disorders",
            "percent": "2.7"
        },
        {
            "name": "Respiratory thoracic and mediastinal disorders",
            "percent": "2.5"
        },
        {
            "name": "Constipation",
            "percent": "2.5"
        },
        {
            "name": "Nausea",
            "percent": "2"
        },
        {
            "name": "Other metabolic and nutrition disorders",
            "percent": "2"
        },
        {
            "name": "Weight gain",
            "percent": "2"
        },
        {
            "name": "Renal and urinary disorders",
            "percent": "19"
        },
        {
            "name": "Nausea",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "10"
        },
        {
            "name": "Constipation",
            "percent": "9"
        },
        {
            "name": "Diarrhea",
            "percent": "80"
        },
        {
            "name": "Mucositis",
            "percent": "10"
        },
        {
            "name": "Acute pulmonary reactions",
            "percent": "9"
        },
        {
            "name": "rare",
            "percent": "80"
        },
        {
            "name": "Genetic mutation",
            "percent": "10"
        },
        {
            "name": "long",
            "percent": "9"
        },
        {
            "name": "term use",
            "percent": "4.5"
        },
        {
            "name": "Myelosuppression",
            "percent": "39"
        },
        {
            "name": "Secondary leukemia",
            "percent": "102"
        },
        {
            "name": "long",
            "percent": "6"
        },
        {
            "name": "term use",
            "percent": "24"
        },
        {
            "name": "Elevated BUN",
            "percent": null
        },
        {
            "name": "Cr",
            "percent": null
        },
        {
            "name": "Hyperuricemia",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Hyperpigmentation",
            "percent": null
        },
        {
            "name": "Skin ulcer",
            "percent": null
        },
        {
            "name": "Gangrenous disorder",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Parvovirus B",
            "percent": null
        },
        {
            "name": "infection",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "bone marrow depression including neutropenia",
            "percent": null
        },
        {
            "name": "X",
            "percent": null
        },
        {
            "name": "L",
            "percent": null
        },
        {
            "name": "reticulocytopenia",
            "percent": null
        },
        {
            "name": "X",
            "percent": null
        },
        {
            "name": "Postmarketing Reports",
            "percent": null
        },
        {
            "name": "L",
            "percent": null
        },
        {
            "name": "macrocytosis",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "X",
            "percent": null
        },
        {
            "name": "L",
            "percent": null
        },
        {
            "name": "anemia",
            "percent": null
        },
        {
            "name": "hemoglobin",
            "percent": null
        },
        {
            "name": "g",
            "percent": null
        },
        {
            "name": "dL",
            "percent": null
        },
        {
            "name": "hemolytic anemia",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "gastrointestinal disturbances",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "gastrointestinal ulcer",
            "percent": null
        },
        {
            "name": "severe hypomagnesemia",
            "percent": null
        },
        {
            "name": "stomatitis",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Elevation of hepatic enzymes",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Skin reactions",
            "percent": null
        },
        {
            "name": "oral",
            "percent": null
        },
        {
            "name": "ungula and cutaneous pigmentation",
            "percent": null
        },
        {
            "name": "oral mucositis",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "melanonychia",
            "percent": null
        },
        {
            "name": "alopecia",
            "percent": null
        },
        {
            "name": "leg ulcers",
            "percent": null
        },
        {
            "name": "cutaneous dryness",
            "percent": null
        },
        {
            "name": "nail hyperpigmentation",
            "percent": null
        },
        {
            "name": "atrophy of skin and nails",
            "percent": null
        },
        {
            "name": "scaling",
            "percent": null
        },
        {
            "name": "violet papules",
            "percent": null
        },
        {
            "name": "cutaneous lupus erythematosus",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Dysuria",
            "percent": null
        },
        {
            "name": "elevations in blood urea nitrogen",
            "percent": null
        },
        {
            "name": "Immune disorders",
            "percent": null
        },
        {
            "name": "Systemic lupus erythematosus",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "drowsiness",
            "percent": null
        },
        {
            "name": "disorientation",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "and convulsions",
            "percent": null
        },
        {
            "name": "Respiratory disorders",
            "percent": null
        },
        {
            "name": "Diffuse pulmonary infiltrates",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "and pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "interstitial lung disease",
            "percent": null
        },
        {
            "name": "pneumonitis",
            "percent": null
        },
        {
            "name": "alveolitis",
            "percent": null
        },
        {
            "name": "allergic alveolitis and cough",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Oligospermia",
            "percent": null
        },
        {
            "name": "azoospermia",
            "percent": null
        },
        {
            "name": "amenorrhea",
            "percent": null
        },
        {
            "name": "General disorders",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "edema",
            "percent": null
        },
        {
            "name": "and asthenia",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Weight gain",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Drug",
            "percent": null
        },
        {
            "name": "induced fever",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "C",
            "percent": null
        },
        {
            "name": "F",
            "percent": null
        },
        {
            "name": "requiring hospitalization reported concurrently with gastrointestinal",
            "percent": null
        },
        {
            "name": "pulmonary",
            "percent": null
        },
        {
            "name": "musculoskeletal",
            "percent": null
        },
        {
            "name": "hepatobiliary",
            "percent": null
        },
        {
            "name": "dermatological or cardiovascular manifestations",
            "percent": null
        },
        {
            "name": "onset typically occurred within",
            "percent": null
        },
        {
            "name": "weeks of initiation and resolved upon discontinuation of hydroxyurea",
            "percent": null
        },
        {
            "name": "upon re",
            "percent": null
        },
        {
            "name": "administration fever re",
            "percent": null
        },
        {
            "name": "occurred typically within",
            "percent": null
        },
        {
            "name": "hours",
            "percent": null
        }
    ]
}